A Cardiomyopeptin Preparation Protects against Isoproterenol-Induced Chronic Heart Failure in Rats ()
ABSTRACT
The
present study investigated the effect of an herbal extract-supplemented
cardiomyopeptin preparation (HECP), in the rat model of chronic heart failure.
HECP pre-/co-treatment at a daily dose of 0.072 to 0.124 g/kg for 30 days
protected against isoproterenol (ISO)-induced chronic myocardial damage in rats
in a dose-dependent manner, with the extent of protection, as assessed by
plasma cardiac troponin I level, being up to 76%. The cardioprotection afforded
by HECP was associated with the enhancement of myocardial mitochondrial
antioxidant status, amelioration of plasma parameters on cardiac dysfunction
and hypertrophy, as well as an increase in myocardial endothelial nitric oxide
synthase activity. Myocardial apoptotic and anti-apoptotic parameters were
suppressed and stimulated, respectively. The cardioprotection afforded by HECP
was accompanied by an increase in exercise capacity, an indirect functional
index of the myocardium, in ISO-challenged rats. In conclusion, HECP may offer
a promising prospect in preventing chronic heart failure in human subjects.
Share and Cite:
Xia, Z. , Leung, H. , Siu, H. , Chan, C. and Ko, K. (2023) A Cardiomyopeptin Preparation Protects against Isoproterenol-Induced Chronic Heart Failure in Rats.
Chinese Medicine,
14, 242-254. doi:
10.4236/cm.2023.144012.
Cited by
No relevant information.